<DOC>
	<DOCNO>NCT02748772</DOCNO>
	<brief_summary>The purpose study determine whether Endostar pump vein Thalidomide effective treatment Advanced Colorectal Cancer ( ACRC ) .</brief_summary>
	<brief_title>Application Two Anti-angiogenesis Drugs Combined With Chemotherapy Advanced Colorectal Cancer Under Background Precision Medical</brief_title>
	<detailed_description>Endostar anti-tumor activity vascular endothelial growth factor . Thalidomide therapeutic insomnia vomit . It also use tumor treatment Anti-angiogenesis drug immune regulator recently year . 1 . Evaluated therapeutic effect survival benefit ACRC treatment use Endostar Thalidomide combine XELOX regimen . ( include RR , DCR , PFS , QOL ) ; 2 . Evaluated security tolerance treat Endostar Thalidomide ( occurrence adverse reaction , degree , regularity control measure , etc . ) ; 3 . Detected histological marker ( VEGF/VEGFR , PDGF/PDGFR , BFGF/FGFR , cox-2 , Her-2 , K-Ras p53 ) patient group . Make retrospective analysis individual molecule indicator guide significant therapy ACRC .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>1 . The patient stage IV colorectal cancer ca n't receive operative treatment diagnose Histopathological cytological examination receive operation conversion therapy . 2 . The niave patient relapse metastasize 6 month ' chemotherapeutic diapause operation adjuvant chemotherapy refuse another operate need operate conversion therapy 3 . Have least one measurable nidus , Ordinary CT MRI scan nidus 20 mm high , Spiral CT PET CT scan nidus 10 mm high . 4 . The first 3 week enter group stop chemotherapy radiotherapy recover previous treatment toxic effect . The patient receive treatment delay toxicity drug ( mitomycin nitrourea ) stop treatment 6 week ; 5 . ECOG score 0 2 point . 6 . Expected survival period 3 month . 7 . Aged 18 75 year age , gender limit . 8 . The electrocardiogram normal body n't unhealed wound . 9 . Peripheral blood cell count , WBC 4.0 x 109 / L high , PLT 80 x 109 / L high , Hb 90 g/L high . 10 . Renal function , Cr 2.0 x UNL ( upper limit normal ) less . 11 . Liver function , AST , ALT 2.5 time normal limit less ( identify liver metastasis , five time normal limit less ) . 12 . Previous severe allergic reaction biological agent , especially e. coli genetically engineer product . 13 . Voluntary participate group , good compliance , willing cooperate test observation sign write informed consent . 1 . Pregnant , lactate woman , female patient fertility ability take contraceptive measure ; 2 . Patients exist serious acute infection controlledï¼›or patient exist purulent infection , chronic infection delay wound heal ; 3 . Patients serious heart disease , include : congestive heart failure , uncontrollable highrisk arrhythmia , unstable angina , myocardial infarction , severe heart valve disease resistant hypertension ; 4 . Patients whose target lesions previously receive radiation therapy topical treatment ( radio frequency , ultrasonic , freeze ) ; 5 . Patients suffer uncontrollable neurological psychiatric disease mental disorder , poor compliance well cope others fail narrative therapy respond ; patient whose primary brain central nervous system metastases disease control Cranial hypertension neuropsychiatric symptom ; 6 . Patients meanwhile participate clinical trial ; 7 . Other circumstance researcher consider patient participate test .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Anti-angiogenesis Drugs</keyword>
	<keyword>Advanced Colorectal Cancer</keyword>
	<keyword>Endostar</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Vascular Endothelial Growth Factor A</keyword>
</DOC>